Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

1 to 16. (canceled)

- (new) A method of treating cancer comprising co-administration of interleukin 18 and a herpes simplex virus that selectively replicates in cancer cells, wherein said interleukin 18 is administered as a protein.
- (new) The method according to claim 17, wherein the herpes simplex virus is a recombinant herpes simplex virus.
 - (new) The method according to claim 17 or 18, wherein the interleukin 18 is administered systemically.
- 20. (new) The method according to claim 19, further comprising local administration of interleukin 12 at a tumor tissue.
- 21. (new) The method according to claim 19, further comprising local administration at a tumor tissue of a recombinant herpes simplex virus that selectively replicates in cancer cells, wherein a gene coding for interleukin 12 has been inserted expressively in the genomic DNA of the recombinant herpes simplex virus.
- (new) The method according to claim 17 or 18, wherein the herpes simplex virus is injected into a tumor tissue.
- 23. (new) The method according to claim 22, wherein the cancer is located separately from the tumor tissue injected with the herpes simplex virus.
- 24. (new) A method according to claim 18, wherein the γ34.5 gene and ICP6 gene of the recombinant herpes simplex virus have been deleted or inactivated.
- (new) A method according to claim 24, wherein the ICP47 gene of the recombinant herpes simplex virus has also been deleted or inactivated.

- 26. (new) A method of treating cancer, comprising administering a recombinant herpes simplex virus that selectively replicates in cancer cells into a tumor tissue and systemically administering interleukin 18 as a protein, wherein the γ34.5 gene and ICP6 gene of the recombinant herpes simplex virus have been deleted or inactivated, and a gene coding for interleukin 12 has been inserted expressively in the genomic DNA of the recombinant herpes simplex virus.
- (new) A method according to claim 26, wherein the ICP47 gene of the recombinant herpes simplex virus has also been deleted or inactivated.